<div>
  <ul>
    <li>
      <p>
        Texas-based AI biopharmaceutical company Lantern Pharma has dosed the first patient in a Phase I clinical trial for its investigational drug, LP-184, in patients with advanced solid tumors and recurrent high-grade gliomas, including glioblastoma.
      </p>
    </li>
    <li>
      <p>
        LP-184 is a small molecule that uses synthetic lethality to target DNA damage repair deficiencies in cancer cells. It has shown anti-tumor activity in various cancer models, including pancreatic, bladder, triple-negative breast cancer, and glioblastoma.&nbsp;
      </p>
    </li>
    <li>
      <p>
        Following the Phase I trial, Lantern plans to advance LP-184 into additional clinical trials for multiple solid tumor indications. Its subsidiary, Starlight Therapeutics, will develop LP-184 for CNS and brain cancers.&nbsp;&nbsp;
      </p>
    </li>
  </ul>
  <p>
  </p>
</div>


<div>
  <p>
    <a href="https://ir.lanternpharma.com/news-events/press-releases/detail/138/lantern-pharma-announces-first-patient-dosed-in-the-phase-1">
      Press release
    </a>
  </p>
</div>


AI Drug Discovery

Lantern Pharma has administered LP-184 to its first patient in a Phase I clinical trial for advanced solid tumors and recurrent high-grade gliomas. LP-184 is a small molecule that targets DNA damage repair deficiencies in cancer cells. It has exhibited anti-tumor activity in different cancer models, including pancreatic, bladder, triple-negative breast cancer, and glioblastoma. After the Phase I trial, Lantern intends to conduct additional clinical trials for multiple solid tumor indications. Its subsidiary, Starlight Therapeutics, will focus on developing LP-184 for CNS and brain cancers.

Lantern Pharma doses first patient in LP-184 Phase I study

Lantern Pharma misses EPS estimate; provides update on clinical progress

Lantern Pharma provides clinical and business updates for Q1 2023

All Updates

Lantern Pharma doses first patient in LP-184 Phase I study

Lantern Pharma misses EPS estimate; provides update on clinical progress

Lantern Pharma provides clinical and business updates for Q1 2023

Lantern Pharma net losses widen for Q4 and 2022

Lantern Pharma forms new subsidiary, Starlight Therapeutics, to focus on CNS and brain cancer treatments

Lantern Pharma to launch first-in-human Phase I clinical trials for two candidates in 2023

Lantern Pharma to launch Phase II clinical trials for oncology candidate in Q3

Lantern Pharma provides clinical update for Q1 2022

Lantern Pharma collaborates with the Danish Cancer Society Research Center

Lantern Pharma releases Q3 2021 financial results